Health Care/Hospital APAC News & Press Release Distribution

Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Plus Paclitaxel/Cisplatin for the First-line Treatment of ESCC at ASCO 2021

SUZHOU, China, June 7, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced data from Phase 2 clinical study (KN046-204) of KN046(PD-L1/CTLA-4 bispecific antibody) plus paclitaxel/cisplatin for the first-line treatment of unresectable locally advanced, recurrent or metastatic e...

2021-06-07 10:11 6414

Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Combined with Chemotherapy for the Treatment of Advanced NSCLC at ASCO 2021

* KN046 combined with platinum doublet chemotherapy is tolerated and has shown promising clinical benefit as IL treatment for stage IV NSCLC. * OS rate at 12 months and 15 months were both 74.9%; Similar survival was observed in patients with PD-L1≥1% and PD-L1<1%; * the median progression-f...

2021-06-07 10:10 6039

Hyperice Named Official Recovery Technology Partner by League of Legends Pro League

SHANGHAI, June 7, 2021 /PRNewswire/ -- League of Legends Pro League (LPL) and Hyperice, the industry leader in recovery technology and pioneer of percussion, vibration, dynamic air compression and thermal technology, today announced a partnership that names Hyperice the league's Official Recovery...

2021-06-07 10:00 2779

Hyperice Named Official Recovery Technology Partner by League of Legends Pro League

OriginCell Therapeutics Presents Positive Results of GPC3 CAR-T in HCC Trial at the 2021 ASCO Annual Meeting

SHANGHAI, June 7, 2021 /PRNewswire/ -- On June 4, 2021 (EST), OriginCell Therapeutics (Shanghai) Co., Ltd. ("OriginCell"), together with Lishui Central Hospital affiliated toZhejiang University and Shanghai Changzheng Hospital, presented the updated data from the on-going trial of Ori-CAR-001,...

2021-06-07 10:00 2914

OriginCell Therapeutics Presents Positive Results of GPC3 CAR-T in HCC Trial at the 2021 ASCO Annual Meeting

BIAL Award in Biomedicine worth 300,000 Euros, nominations until 30 June

PORTO, Portugal, June 7, 2021 /PRNewswire/ -- The second edition of the BIAL Award in Biomedicine is currently underway. Worth three hundred thousand Euros, this prize is intended to reward a work with exceptional quality results and scientific relevance published in the last ten years in the bro...

2021-06-07 10:00 1346

Poster Highlighting Clinical Data of KN046 Plus Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Pancreatic Cancer Is Presented at ASCO 2021

* As of January 15, 2021, 9 patients were included in the efficacy analysis and 17 patients in the safety analysis. ORR was 55.6%, and DCR was 88.9%. * The updated results from this Phase II study will be presented at an upcoming medical meeting. A phase III clinical study of KN046 in combinat...

2021-06-07 09:53 5601

Ascletis Received China IND Approval of Its FXR Agonist ASC42 for Chronic Hepatitis B Indication

HANGZHOU, China and SHAOXING, China, June 7, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its drug candidate ASC42 to conduct clinical trials for ch...

2021-06-07 08:30 2706

Arctic Vision Announces Exclusive Licensing Agreement with Olympic Ophthalmics for iTEAR®100 for the Treatment of Dry Eye Disease in Greater China, South Korea and ASEAN countries

ISSAQUAH, Wash. and SHANGHAI, June 7, 2021 /PRNewswire/ -- Arctic Vision, a clinical stage biotech company focusing on innovative ophthalmology therapies for pan-ocular diseases, and Olympic Ophthalmics, a U.S.-based medical technology company pioneering neuromodulation treatments for ophthalmic ...

2021-06-07 08:00 1895

Innovent and HUTCHMED Release Phase 1b preliminary Results of TYVYT (Sintilimab Injection) plus Fruquintinib as a Third Line Treatment for Advanced Colorectal Cancer at ASCO Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-06-07 08:00 6843

Innovent and AnHeart Release Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-06-07 08:00 6980

Innovent Releases the Phase Ia/Ib Dose-Escalation Trial Results of IBI110 (anti-LAG-3) in Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-06-07 08:00 7171

Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-06-07 08:00 7038

Samsung Pharm & GemVax present pancreatic cancer immunotherapeutic drug, RIAVAX™, phase III results at ASCO 2021

SEOUL, South Korea, June 5, 2021 /PRNewswire/ -- Samsung Pharm Co., Ltd. announced today that the company presented the results of a phase III clinical trial of its pancreatic cancer immunotherapeutic drug candidate called 'RIAVAX™ (GV1001)' conducted in Korea at the 2021 American Society of Clin...

2021-06-05 20:00 2982

Singapore/ US based TurtleTree ready to commercialize Human Lactoferrin as first major product

SINGAPORE, June 5, 2021 /PRNewswire/ -- TurtleTree, the pioneer of cell-based milk, is now preparing for the launch of its first commercially scalable product. Human Lactoferrin lately also referred to as pink gold because of it's amazing properties for boosting immunity, resistance to infections...

2021-06-05 01:32 3495

Singapore/ US based TurtleTree ready to commercialize Human Lactoferrin as first major product

Advaccine Announces First Participants Dosed in Phase 2 Study of ADV110 Evaluating Respiratory Syncytial Virus (RSV) Vaccine Candidate in Australia

SUZHOU, China, June 4, 2021 /PRNewswire/ -- Advaccine Biopharmaceuticals ("Advaccine") announces that the first participants have been successfully dosed in its phase 2 study of ADV110, a respiratory syncytial virus (RSV) prophylactic vaccine candidate, inAustralia. The phase 2 study is a two-ce...

2021-06-04 20:05 3251

Second Global Health Forum of Boao Forum for Asia Deepens Understanding of Universal Health and Global Cooperation

QINGDAO, China, June 4, 2021 /PRNewswire/ -- The Boao Forum for Asia (BFA) hosts the second Global Health Forum (The Forum) inQingdao. With rising consensus in the health field in the context of the pandemic, the Forum, with the aim of achieving the shared vision of "Health for All", saw partners...

2021-06-04 20:03 3149

Second Global Health Forum of Boao Forum for Asia Deepens Understanding of Universal Health and Global Cooperation

WhaleTeq Launches First AED Management Platform with DFS200 to Provide Most Effective and Efficient Maintenance Solution

TAIPEI, June 4, 2021 /PRNewswire/ -- WhaleTeq, a Taiwan-based Innovative medical device testing solution company, launches the first AED management platform with their latest defibrillator tester, DFS200, to fill in the AED testing and maintenance gap. AED testing and maintenance is of great impo...

2021-06-04 19:38 3760

WhaleTeq Launches First AED Management Platform with DFS200 to Provide Most Effective and Efficient Maintenance Solution

VeChain, Together With DNV, Enables Renji Hospital To Launch The World's First Blockchain-based IVF Service App - MyBaby

SHANGHAI, June 4, 2021 /PRNewswire/ -- In partnership with VeChain and DNV, Renji Hospital, a top-ranking hospital inChina affiliated with the Shanghai Jiaotong University School of Medicine has announced the launch of smart medical care project - MyBaby, the world's first blockchain-based In-Vit...

2021-06-04 18:39 6140

VeChain, Together With DNV, Enables Renji Hospital To Launch The World's First Blockchain-based IVF Service App - MyBaby

Oxygen Concentrators have arrived, 135 oxygen concentrators donated by Fosun and its friendly enterprises arrive in Mumbai

HONG KONG, June 4, 2021 /PRNewswire/ -- On 1 June 2021, 135 oxygen concentrators, 5 ventilators, and 3,300 KN95 masks donated by Fosun Foundation ( Shanghai) (hereinafter referred to as "Fosun Foundation") and its friendly enterprises arrived inMumbai. This is the largest batch of oxygen concentra...

2021-06-04 16:48 2175

Sihuan Pharmaceutical (0460.HK) Obtained the Exclusive Distribution Right for LipiVage(R) Fat Collection System in Greater China and South Korea

HONG KONG, June 4, 2021 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; Hong Kong Stock Exchange stock code: 0460) is pleased to announce that Meiyen Laboratory Inc, an Am...

2021-06-04 14:03 8969